Related Experiment Video

Updated: Jul 19, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future

Judith A Hobert1, Glyn Dawson

  • 1Committee on Molecular Metabolism and Nutrition, Biological Sciences Division, University of Chicago, Chicago, IL 60637, USA.

Biochimica Et Biophysica Acta
|October 20, 2006
PubMed

Insights

Neuronal Ceroid Lipofuscinoses (NCLs) treatments have historically failed to halt disease progression. Current research explores novel therapies like gene and stem cell therapy to improve patient outcomes.

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • Neuronal Ceroid Lipofuscinoses (NCLs) are a group of rare, inherited neurodegenerative disorders.
  • Current treatments offer limited efficacy in altering disease progression or improving patient lifespan.
  • Significant unmet need exists for effective therapies for NCLs.

Purpose of the Study:

  • To review historical therapeutic approaches for NCLs.
  • To discuss emerging and currently investigated treatment strategies for NCLs.
  • To examine future therapeutic possibilities for NCL patients.

Main Methods:

  • Literature review of past, present, and future NCL therapies.
  • Analysis of therapeutic mechanisms and clinical trial outcomes.
  • Synthesis of findings to provide a comprehensive overview.

Main Results:

  • Historical therapies showed minimal impact on NCL disease progression.
  • Emerging strategies including chaperone, enzyme replacement, gene, and stem cell therapies are under investigation.
  • No single therapy has yet arrested NCL progression or significantly extended life.

Conclusions:

  • Novel therapeutic strategies hold promise for altering NCL disease course.
  • Further research and clinical trials are crucial for developing effective NCL treatments.
  • Future therapies may offer improved quality of life and duration for NCL patients.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Intravitreal Injections in the Ovine Eye03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...